Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine in Patients with Chronic Obstructive Pulmonary Disease — Hebei Province, China, September−December, 2019

WHAT IS ALREADY KNOWN ON THIS TOPIC? The global burden of chronic obstructive pulmonary disease (COPD) is serious. Pneumococcal infection is associated with acute exacerbations of COPD (AECOPD). The 23-valent pneumococcal polysaccharide vaccine (PPSV23) is recommended for COPD patients to decrease A...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yan, Ma, Ying, An, Zhijie, Yue, Chenyan, Wang, Yamin, Wang, Liye, Liu, Yunqiu, Yuan, Xiaodong, Zhang, Shuping, Ye, Qiang, Li, Hong, Li, Keli, Yin, Zundong, Wang, Huaqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2021
Materias:
Preplanned Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393071/
https://www.ncbi.nlm.nih.gov/pubmed/34594878
http://dx.doi.org/10.46234/ccdcw2021.089

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393071/
https://www.ncbi.nlm.nih.gov/pubmed/34594878
http://dx.doi.org/10.46234/ccdcw2021.089

Ejemplares similares